Ore Pharmaceuticals Inc.
Ore Pharmaceuticals Begins Clinical Trial of GL1001
Published in Obesity and Diabetes Week, October 13th, 2008
Ore Pharmaceuticals Inc. (NASDAQ: ORXE) announced that it has initiated dosing subjects with GL1001, the Company's lead drug candidate, in a multiple ascending dose clinical trial. GL1001, the first clinical-stage inhibitor of the ACE2 enzyme, is an orally administered small molecule that has decreased several disease activity measures in in vivo models of inflammatory bowel disease (IBD) and gastritis. GL1001 was administered previously in a Phase I single ascending dose clinical study completed in the United Kingdom, where it was well tolerated and exhibited favorable pharmacokinetics consistent with once daily dosing. Ore Pharmaceuticals is pursuing the clinical development of GL1001 in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- American Gastroenterological Association
Genes influence effectiveness of weight-loss drug - Elsevier Health Sciences
New study indicates link between weight gains during pregnancy and dieting history - Federation of American Societies for Experimental Biology
Scientists discover why a mother's high-fat diet contributes to obesity in her children - JAMA and Archives Journals
Gene variation associated with decreased risk of colorectal cancer - Norwegian Institute of Public Health
Thin men more vulnerable to osteoporosis and bone fractures than other older men - Springer
Carrots and sticks to promote a healthy lifestyle? - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
